Trial Profile
Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 20 Nov 2017 New trial record